AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06606821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Investigational drug will be administered as a sc. injection once-weekly.
Study NCT06606821 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo containing the same excipients and volume as the active treatment arm but without tirzepatide will be administered as a sc. injection once-weekly.
Study NCT06607029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: the opioid-based control group
Description: Intraoperative analgesia will be administered with conventional opioid drugs such as sufentanil and remifentanil.
Study NCT06607029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: the opioid-free anesthesia group
Description: The patients will be administered with an opioid-free strategy during surgery. The investigator will use esketamine, dexmetopidine, and local anesthesia to control perioperative pain.
Study NCT06607419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Recruited patients will receive Blinatumomab since day 29 of induction for 14 days.
Study NCT06606652 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Acute caffeine intake (3 mg/kg)
Study NCT06606652 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Acute placebo intake (3 mg/kg of maltodextrin)
Study NCT06606522 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical model
Description: Clinical model: a clinical model based on basic demorgraphic information and commonly executed laboratory tests to differentiate different pathological types of intrinsic AKD.
Study NCT06606522 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary biomarkers
Description: Urinary biomarkers: biomarkers help differentiate different pathological types of intrinsic AKD.
Study NCT06604910 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: branched chained amino acid
Description: patients undergoing branched chained amino acid
Study NCT05403593 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No intervention, prospective data collection
Study NCT05967741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Erythritol
Description: Erythritol is a naturally occurring and non-nutritive sugar alcohol that is classified as generally recognized as safe (GRAS)
Study NCT05967741 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Aspartame
Description: Aspartame consists of two amino acids, phenylalanine and aspartic acid, and a methyl group. It does not have metabolic effects and has served as the blinded control beverage in the investigators' completed NIH-funded clinical trials.
Study NCT04309877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline ER
Description: Capsules of theophylline ER
Study NCT04309877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PO placebo
Description: Capsules of methylcellulose
Study NCT04309877 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PO placebo
Description: Capsules of methylcellulose
Study NCT04309877 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide (LPS)
Description: Purified bacterial wall component as an inflammatory challenge
Study NCT04309877 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IV placebo
Description: Normal (0.9%) saline
Study NCT04309877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IV placebo
Description: Normal (0.9%) saline
Study NCT06379958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leramistat 40mg
Description: Oral capsule
Study NCT06379958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole 200 mg
Description: Oral capsule
Study NCT06379958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenytoin 100 Mg Oral Capsule
Description: Oral capsule
Study NCT06379958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 40mg
Description: Oral capsule
Study NCT06379958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Upadacitinib 15 MG
Description: Oral Capsule
Study NCT05209802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group A: High intensity exercise training
Description: Both group will receive aquatic exercise training twice a week for 12 weeks at different intensities
Study NCT05209802 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group B: moderate intensity exercise training
Description: Both group will receive aquatic exercise training twice a week for 12 weeks at different intensities
Study NCT06508125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: non-cross-linked hyaluronic acid
Description: non-cross-linked hyaluronic acid injection with physical therapy
Study NCT04807647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orhan OSMAN's track Don't Let Your Baby Cry in the Kolik album will be played on the music player.
Description: white noise will be played while breastfeeding
Study NCT04779554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C, flat dose 40 mg
Description: Mitomycin C will be delivered as heated intraperitoneal chemotherapy (HIPEC) in two flat doses. Dose 1 will be 30mg at minute 0 and dose 2 will be 10 mg at minute 60.
Study NCT05340868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Pill
Description: Oral semaglutide treatment
Study NCT05619081 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POWERNAP
Description: POWERNAP of max 30min while participants ly down comfortably
Study NCT05412654 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High potassium water
Description: High potassium water Potassium 6.2 mg/100ml
Study NCT05412654 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control low potassium water
Description: Control water Potassium 0.2 mg/100ml
Study NCT06245330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-001
Description: liquid formulation for Intravenous infusion
Study NCT04779554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C, weight-based dose 12.5 mg/m2
Description: Mitomycin C will be delivered as heated intraperitoneal chemotherapy (HIPEC) in two weight-based doses of 9 mg/m2 at minute 0 and 3 mg/m2 at minute 60.
Study NCT05769257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IS-001
Description: Intravenous injection of IS-001 investigational drug
Study NCT06398119 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Treatment Program
Description: Traditional Treatment Program for improving hand function
Study NCT06398119 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Treatment Program
Description: Traditional Treatment Program for improving hand function
Study NCT06398119 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Program
Description: Virtual Reality Program for improving hand function
Study NCT06398119 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Program
Description: Virtual Reality Program for improving hand function
Study NCT06006013 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT06006013 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT06006013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO
Study NCT05236569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid injection
Description: The tranexamic acid injection was given intradermally to the facial skin
Study NCT05236569 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Injection Water
Description: The 0.9% normal saline injection was given intradermally to the facial skin
Study NCT05145452 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish-oil derived n-3 polyunsaturated fatty acids
Description: 4.2 g/d (7 pills with 600 mg each)
Study NCT05145452 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fish-oil derived n-3 polyunsaturated fatty acids
Description: 4.2 g/d (7 pills with 600 mg each)
Study NCT06006013 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06006013 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05295043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (CDK)4/6 inhibitor
Description: CDK4/6 inhibitor + AI/fulvestrant therapy，According to clinical guidelines or drug instructions, the treating physician will adjust the drug dose in accordance with the clinical reality and the patient's personal situation.
Study NCT04998461 — intervention group
Intervention type: BIOLOGICAL
Intervention: urine collection
Description: To isolate urine stem cells, a sample of 30ml minimum an 100ml maximum as a function of the patient, will be collected in a single time in a sterile flask during collection for the nephrologic exams. A transcriptome analysis of USC will be performed.
Study NCT05436392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Comparison Feedback
Description: USAP anesthesia providers will receive monthly alerts via USAP's smartphone-based practice management application, text message, or email presenting individual-level data on their benzodiazepine administration patterns versus other USAP providers, using data from the USAP clinical and quality data warehouse.
Study NCT05436392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Informational Letter
Description: Breif informational letters will be distributed to eligible patients within the 2 weeks prior to surgery. Letters will be produced on USAP letterhead and signed by the USAP Chief Quality Officer. Letter text will state USAP's commitment to brain health and avoiding potentially unnecessary medications for patients undergoing surgery. It will also include a statement encouraging patients to discuss anesthesia plans with their clinicians at the time of surgery to aid tailoring of care to individual needs. Letters will be distributed directly to patients via text link, email, or hard copy as a component of standard pre-operative instructional communications and other educational and patient outreach materials related to clinical care.
Study NCT05627154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Serotonin-reuptake inhibitor commonly used to treat depressive and anxiety disorders.
Study NCT05627154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Activation
Description: A NICE recommended psychological intervention for mild to moderate depression. In behavioural activation, the person with depression and the therapist work together to identify the relationships between the activities the person undertakes and their mood. It encourages people to become less mood-dependent when planning activities and doing constructive things that they would usually avoid doing.
Study NCT05627154 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A lactose-based tablet.
Study NCT05160220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin
Description: 0.5 g dried Psilocybe cubensis mushroom material, 0.8 mg psilocybin.
Study NCT05160220 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 g dried edible non-psychoactive mushroom material.
Study NCT05296759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin A
Description: botulinum toxin A injection
Study NCT05296759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin oral intake
Study NCT05296759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Duloxetine oral drug intake
Study NCT06511557 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non immersive virtual reality ( xbox kinetic)
Description: Treatment starts with a gentle warm-up i.e. hot pack for 10 minutes and gentle stretching of Quadriceps, hamstrings and calves. Each game was performed for 10 minutes with 1 minute rest between games. 3 sessions Per Weeks for 8 weeks (45 Min per Session) were given. All the exergames target muscles like Hamstring, Quadriceps and calves to improve function of knee joint and reduce pain.~Baseline assessment was done at the start of the session and proper cool down and stretching will be performed at the end of each session to promote flexibility and reduce muscle soreness
Study NCT06511557 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinetic chain exercises
Description: Session starts with a gentle warm-up i.e. Hot pack for 10 minutes and gentle stretching. Each exercise is performed in 2 sets, each set of 10 repetitions with 1min rest between sets. 3 sessions Per Weeks for 8 weeks (45 Min Per Session) were given .Kinetic chain exercises involve integrated movements that engage multiple joints and muscle groups \& focus on strengthening muscles like quadriceps, hamstrings, glutes, and calf muscles, improving joint stability, function, and reducing pain. Baseline assessment was done at the start of the session and proper cool down and stretching was performed at the end of each session to promote flexibility and reduce muscle soreness
Study NCT05022199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPY fluorescent angiography
Description: This group has had SPY fluorescent angiography used intraoperatively during urinary diversion. To be compared with historic controls who did not.
Study NCT04827550 — intervention group
Intervention type: OTHER
Intervention: STUDY
Description: Fibromyalgia Patient
Study NCT05115240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body Scan
Description: The body scan intervention aims to raise one's awareness of one's own body. It is considered a relaxation, meditation or mindfulness intervention. During the body scan participants will walk through his or her body by focusing their mind on specific body parts without analyzing, judging or reacting.
Study NCT05115240 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Audio-book
Description: Participants listen to an audio book for the same amount of time as the body scan groups
Study NCT06633159 — intervention group
Intervention type: DEVICE
Intervention: MitraClip
Description: surgical intervention to correct mitral regurgitation by percutaneous transcatheter implantation of the MitraClip G4 clip on the mitral valve leaflets
Study NCT06632808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Deep cervical flexor muscle exercises target the deep neck muscles that play a crucial role in the stabilization of the cervical spine and the maintenance of proper posture. These muscles, particularly the longus colli and longus capitis, are responsible for the correct alignment of the head and neck. The exercises typically involve gentle flexion of the neck (bringing the chin towards the chest) with low-intensity, controlled movements. The goal is to strengthen these muscles, enhance spinal stability, and alleviate symptoms such as tension-type headaches. Additionally, these exercises support postural control and can reduce excessive strain on the neck.
Study NCT06415344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTX-102
Description: Antisense Oligonucleotide
Study NCT05277714 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The sham protocol will last 15 minutes per session, and during each session, the participants will receive the same instruction but will be shown a random signal, the goal being that the control strategy that the participant tries to implement is not correlated with the visual feedback provided by the gauge.
Study NCT05277714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NF
Description: The neurofeedback protocol will be the same during the 8 sessions constituting the protocol and taking place over a period of 4 weeks (2 neurofeedback sessions per week, the first and the last one in an MRI context). It will last 15 minutes per session, and during each session, the patient will have to increase the brain activity of her dlPFC using a visual gauge representing the activity level of her own dlPFC. No specific instructions will be given to the volunteer so that he/she can develop his/her own internal strategy to increase this activity level.
Study NCT04919499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765128
Description: BI 765128
Study NCT04919499 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Description: Sham comparator
Study NCT06696105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resin infiltration
Description: Icon® resin infiltration (DMG America, Englewood, NJ, US) technique utilizes light-cured hydrophilic and low viscosity resins that can permeate WSL subsurface micropores. Resin modified glass ionomer cement includes Fluoroaluminosilicate glass, which facilitates the interaction of fluoride with the enamel surface resulting in an instant release . Concurrently, the predominant glass matrix serves as source of fluoride for the purpose of continuous release, hypothesized to facilitate remineralization.
Study NCT06696105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vanish XT varnish (resin modified glass ionomer restoration)
Description: Resin modified glass ionomer cement includes Fluoroaluminosilicate glass, which facilitates the interaction of fluoride with the enamel surface resulting in an instant release. Concurrently, the predominant glass matrix serves as source of fluoride for the purpose of continuous release, hypothesized to facilitate remineralization.
Study NCT06699199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver diamine Fluoride 38%
Description: Intervention is the application of Silver diamine fluoride 38% to children Group in arm 1 (Arm 1): children will receive Silver diamine fluoride 38% application for 1 min to arrest primary teeth~SDF: (Silver diamine fluoride 38% is a material used for arresting caries lesions in primary and permanent teeth)~- SDF Product generic name and information (E-SDF: it is a 1-step Technique) - The 38% SDF solution comprised a blend of silver, fluoride, and ammonia at a total concentration of 38%.
Study NCT06699199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride- potassium iodide
Description: Intervention is the application of Silver diamine fluoride 38% + potassium iodide to children Group in arm 2 (Arm 2): children will receive Silver diamine fluoride 38% application for 1 min to arrest primary teeth, Followed by an second minute of potassium iodide solution application~- SDF Product generic name and information (Riva-star: it is a 2-step Technique) 30-35% SDF solution (1st step) comprised a blend of silver, fluoride, and ammonia applied in combination with a second application of potassium iodide solution (2nd step)
Study NCT06699095 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Patients will perform a 12 weeks rehabilitation program through telemedicine at home after intensive rehabilitation in hospital. Balance rehabilitation program will be scheduled on the patients' need and ability to be performed three times a week with high levels of satisfaction and safety at home under remote control of the physical therapist.
Study NCT06699407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qishenyiqi dripping pills
Description: Qishenyiqi dripping pills, 1 bag once, three times a day, 12 months
Study NCT06777537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talniflumate
Description: Talniflumate was administered
Study NCT06236841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XH-S004 tablet
Description: XH-S004 tablets will be administered orally as per assigned treatment regimen on schedualed days.
Study NCT06236841 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: XH-S004 placebo tablet
Description: XH-S004 placebo tablet (matched) will be administered orally as per assigned treatment regimen on schedualed days.
Study NCT05281523 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Depemokimab (GSK3511294)
Description: Depemokimab (GSK3511294) will be administered using a pre-filled syringe.
Study NCT05281523 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as normal saline using a pre-filled syringe.
Study NCT06699407 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 1 bag once, three times a day, 12 months
Study NCT04590313 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthrodesis
Description: MTPJ I arthrodesis
Study NCT05491941 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sepsis Bundle
Description: Intervention initiated within 1 hour or 3 hours of presentation depending on the Arm: 1. Measure lactate level. 2. Obtain blood cultures before administering antibiotics. 3. Administer broad-spectrum antibiotics. 4. Begin rapid administration of 30ml/kg crystalloid for hypotension or lactate greater than or equal to 4mmol/L. 5. Apply vasopressor if hypotensive during or after fluid resuscitation to maintain a mean arterial pressure greater than or equal to 65 mm Hg.
Study NCT05211804 — intervention group
Intervention type: DRUG
Intervention: Ophthalmic Drugs
Description: Patients will receive the same treatment as if not a part of the project